Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 869.

https://doi.org/10.1182/blood-2024-203163

Published: 2024

Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad

Blood (2024) 144 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2024-203139

Published: 2024

Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot

Blood (2023) 142 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2023-188771

Published: 2023

Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta

Blood (2022) 140 (Supplement 1): 7070–7071.

https://doi.org/10.1182/blood-2022-157927

Published: 2022

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Aarif Ahsan, Ann Polonskaia, Chih-Chao Hsu, Chad C Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis, Michael Pourdehnad, Erin Flynt, Aarif Ahsan, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2658.

https://doi.org/10.1182/blood-2021-150641

Published: 2021

Journal Articles

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Jian Kang, Hsiling Chiu, Archana Mukhopadhyay, Krista Wollerman, Michael Pourdehnad, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2021-153907

Published: 2021

Journal Articles

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

Daniel W. Pierce, Tsun-Wen Sheena Yao, Emily Pace, Hongbin Wang, Pierre Flandin-Blety, Alicia Benitez, Carla Guarinos, Matthew Hoffmann, Soraya Carrancio, Jinhong Fan, Michael Pourdehnad

Blood (2021) 138 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2021-147160

Published: 2021

Journal Articles

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2021-153994

Published: 2021

Journal Articles

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Blood (2021) 137 (5): 661–677.

https://doi.org/10.1182/blood.2020008676

Published: 2021

Includes: Supplemental data

Journal Articles

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137161

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Alberto Risueño, Patrick R. Hagner, Fadi Towfic, Celia Fontanillo, Amira Djebbari, Joel S. Parker, Clifton P. Drew, Grzegorz S. Nowakowski, Matthew J. Maurer, James R. Cerhan, Xin Wei, Yan Ren, Chung-Wein Lee, Suzana Couto, Maria Wang, Michael Pourdehnad, Anita K. Gandhi, Matthew W. B. Trotter

Blood (2020) 135 (13): 1008–1018.

https://doi.org/10.1182/blood.2019002414

Published: 2020

Includes: Supplemental data

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 3940.

https://doi.org/10.1182/blood-2019-128450

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

NARROW

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only